Taking stock of the drug industry, from the lab to the medicine chestMay 9, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Justin Sullivan/Getty Images STAT+ | Gilead defeats federal government in closely watched battle over patents for HIV prevention pills The battle marked the first time that the U.S. government had filed a patent infringement lawsuit against a pharmaceutical company. By Ed Silverman STAT+ | What to know about a pivotal FDA hearing on Sarepta's gene therapy for Duchenne On Friday, a committee of advisers to the FDA will meet to discuss the company's experimental gene therapy for Duchenne muscular dystrophy. By Jason Mast STAT+ | What FDA mandate? Sun Pharma halts shipments from a plant with a troubled history The FDA found that Sun Pharmaceuticals has failed to comply with a mandate to address shortcomings at a plant in India. By Ed Silverman Scott Eisen/Getty Images STAT+ | Q&A: Sen. Sanders on insulin costs and his committee's generic drug kerfuffle "Both [drugmakers and PBMs] share major responsibility for the outrageously high prices that we pay," Sen. Bernie Sanders told STAT. By Sarah Owermohle Who's in charge of the White House Covid response after the emergency ends? The White House isn't quite ready to launch its new pandemic response office for a neat handoff at the end of the Covid-19 emergency. By Rachel Cohrs More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments